NemaGen's recent breakthrough has identified a requirement for the metabolic enzyme Car1 in mast cell development. We are advancing these findings by developing novel chemical compounds to target Car1 and prevent mast cell-mediated inflammation. This innovative program seeks to develop much needed treatments for allergic inflammation, mastocytosis and other mast cell-related diseases.
NemaGen's cutting-edge neuroimmunology studies have revealed that the neuropeptide NMB is a potent inhibitor of lung inflammation. Lung diseases including COVID-19 represent the leading cause of death in the world and novel therapeutics are desperately needed to prevent lung inflammation. This program is advancing NMB delivery strategies to treat both acute and chronic inflammatory responses in the lung.